This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: General pharmacology, Subject name: Pharmacology
[{'content': 'By binding RANKL with high affinity, which of the following drug reduces bone resorption \nSelect and explain. \nA. Alemtuzumab, B. Palivizumab, C. Daclizumab, D. Denosumab', 'role': 'user'}, {'content': 'Answer: D \nExplanation: By binding to RANKL,denosumab inhibitsRANKL from activating its only receptor RANKon the surface of osteoclasts and their precursors. Prevention of RANKL-RANKinteraction inhibits osteoclast formation, function, and survival; thereby decreasing bone resorption and interrupting cancer-induced bone destruction Ref essentials of pharmacology, k. D tripati 5e', 'role': 'assistant'}]